ArticleJournal for immunotherapy of cancer2022

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Ines Pires da Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.